1049 GMT - Investors are looking for evidence of GSK's pipeline progress as the patent for its HIV drug Dolutegravir will expire from 2028 in the U.S., Berenberg analysts say in a note. The British pharma giant's key growth drivers include its shingles vaccine Shingrix, its RSV shot Arexvy, HIV drugs Dovato, Cabenuva, Apretude and its lupus treatment Benlysta and asthma drug Nucala, the analyst say. GSK is expected to post sales and earnings growth in line with European non-obesity peers over the 2023-27 time period, driven by both its pharmaceuticals and vaccines units, Berenberg says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 05:50 ET (10:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。